Therefore, TLR9-targeted delivery of STAT3 inhibitors, as single agents or in combination with T cell-based approaches, offers a novel strategy for safer and more effective immunotherapy of BCL and, potentially, other hematologic malignancies. Here, TLR9 is linked to hematologic disorder.